SYNGENE - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.9
| Stock Code | SYNGENE | Market Cap | 19,009 Cr. | Current Price | 472 ₹ | High / Low | 761 ₹ |
| Stock P/E | 49.6 | Book Value | 115 ₹ | Dividend Yield | 0.26 % | ROCE | 12.8 % |
| ROE | 9.78 % | Face Value | 10.0 ₹ | DMA 50 | 591 ₹ | DMA 200 | 649 ₹ |
| Chg in FII Hold | -1.35 % | Chg in DII Hold | 1.21 % | PAT Qtr | 68.7 Cr. | PAT Prev Qtr | 66.2 Cr. |
| RSI | 16.9 | MACD | -47.0 | Volume | 7,67,650 | Avg Vol 1Wk | 12,23,246 |
| Low price | 456 ₹ | High price | 761 ₹ | PEG Ratio | 38.4 | Debt to equity | 0.07 |
| 52w Index | 5.24 % | Qtr Profit Var | -44.2 % | EPS | 8.22 ₹ | Industry PE | 78.8 |
📊 SYNGENE currently shows weak potential for swing trading. The stock is trading well below its 50 DMA (591 ₹) and 200 DMA (649 ₹), indicating strong bearish momentum. RSI at 16.9 suggests the stock is deeply oversold, while MACD at -47.0 confirms negative sentiment. Valuation is high with a P/E of 49.6 compared to the industry average of 78.8, but PEG ratio of 38.4 signals overvaluation relative to growth. Fundamentals are modest with ROCE at 12.8% and ROE at 9.78%, while quarterly profit variation (-44.2%) highlights earnings pressure. Overall, the stock may offer a short-term technical rebound but remains risky for swing trading.
✅ Optimal Entry Price: Around 460–470 ₹ (near support levels)
🚪 Exit Strategy: If already holding, consider booking profits near 500–520 ₹ resistance zone, or exit if price falls below 455 ₹ support.
Positive
- Strong institutional support from DII (+1.21%)
- Low debt-to-equity ratio (0.07), showing financial stability
- EPS of 8.22 ₹ supports earnings base
- Book value of 115 ₹ provides some fundamental backing
Limitation
- Stock trading far below both 50 DMA and 200 DMA
- RSI at 16.9 indicates oversold but also weak momentum
- PEG ratio (38.4) suggests significant overvaluation
- Dividend yield at 0.26% is minimal
Company Negative News
- Quarterly PAT decline (68.7 Cr vs 66.2 Cr with -44.2% variation)
- FII holdings decreased (-1.35%), showing reduced foreign investor confidence
Company Positive News
- DII inflows indicate domestic investor trust
- Stable financial structure with low debt
Industry
- Biotech and pharma research sector remains in long-term growth phase
- Industry PE at 78.8, showing SYNGENE trades at a discount
- Sector outlook supported by demand for contract research and innovation
Conclusion
⚖️ SYNGENE is a weak candidate for swing trading due to poor technicals and declining profits. Entry near 460–470 ₹ may offer a short-term rebound, but profit booking should be considered around 500–520 ₹. Caution is advised as momentum remains bearish despite sector resilience.